{"title": "PDF", "author": "PDF", "url": "https://www.fhi.no/globalassets/dokumenterfiler/rapporter/2020/amr-kunnskapshull-rapport.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "2020 RAPPORT ANTIBIOTIKARESISTENS Kunnskapshull, . Status 2020. [Antimicrobial resistance - knowledge gaps, challenges and relevant measures. Status 2020. Rapport 2020. Oslo: Folkehelseinstituttet, 20 20. 3 Antibiotikaresistens hos mennesker er til import av AMR. Norge b\u00f8r 2020 Folkehelseinstituttet Executive Summary Antimicrobial resistance (AMR) is a global threat to the health and welfare of humans and animals. The basic understanding of AMR has not changed over the last decade, but we have gained more detailed insights into how resista nce arises, is selected for and spreads within and between humans, animals, and the environment. It is necessary to see the challenges associated with AMR in a holistic \"One Health\" perspective. Norway's primary cross -sectoral challenge is how to maintain the current favorable AMR status in humans, animals, and the food supply. As a precautionary principle, the development and spread of AMR should be limited through targeted measures against documented resistance drivers. The key measures will continue to b e related to reducing the need for antibiotics, improving the quality of prescribing, and preventing the spread of resistant bacteria. However, the best way to achieve these measures has not yet been identified. The Norwegian National Strategy against Ant ibiotic Resistance (2015 -2020) primarily focused on reducing the consumption of antibiotics in humans and animals. The goals for the human health service have largely been achieved, both in terms of total human consumption of antibiotics and the use of par ticularly resistance -driving antibiotics in healthcare institutions. There is not a sufficient basis to recommend new, specific measures for a general reduction of human antibiotic use. Rather we propose several measures that can improve the quality of pre scribing. For animals, including farmed fish, all the reduction targets have been reached, and there is no evidentiary basis for recommending new general reduction targets. Good infection prevention and control measures can avert infections and the spread of resistant microbes. The Norwegian government published the National Action Plan for Better Infection Prevention and Control within the Health Service in 2019. The expert group emphasizes the need to follow up and further develop the measures in this act ion plan. Targeted preventative measures outside healthcare institutions as well as continuous efforts to improve animal health are also crucial to limit the spread of infections and thereby preserve low levels of antibiotic use in both humans and animals . The expert group proposes several measures in this area, including increased research investment. Naturally occurring, resistant bacteria are found in all environments. Additionally, resistant bacteria, resistance genes, and chemicals that select for an tibiotic resistance may be released into the environment, which can thus function both as a reservoir and provide a route of dispersal. There are considerable knowledge gaps related to the role of the environment in the development and spread of resistant bacteria and resistance genes, including possible transfer between domestic and wild animals as well as humans. It is therefore important to strengthen the knowledge base regarding the role of the environment in the development and spread of antibiotic res istance in Norway and globally. There are few and small- scale studies on antibiotic resistance in the environment. The detection methods vary widely, making it difficult to compare results across studies. Research is needed to develop standardized methods for the detection of AMR in environmental bacteria from a variety of ecosystems. Furthermore, there is a need for greater evidence from comprehensive studies on different inputs and distribution routes for AMR in the environment, based on standardized meth ods. This can provide a basis for determining whether and what type of environmental AMR monitoring is suitable for Norway. 6 Antibiotikaresistens - Kunnskapshull, utfordringer og aktuelle tiltak . Status 2020 Folkehelseinstituttet The Norwegian AMR situation is favourable compared to most other countries, yet this leads to some unique challenges and obligations . AMR may be imported to Norway through human travel, cross -border trade of animals, and import of food. Norway, together with countries in a similar situation, should promote both basic and applied research as well as innovation targeted to our specific c hallenges. Norway must also support global initiatives and individual countries to improve their AMR situations. Norway has a strong self- interest in strengthening health preparedness through the development of new diagnostics, antibiotics and alternative treatment strategies, increased security of supply for critical medicines, and generally improving the global AMR situation. 7 Antibiotikaresistens - Kunnskapshull, 1.1 Bakgrunn for helsetjeneste 31 4 Dyr, planter og mat _______________________________________________________________ 36 4.1 Innledning 36 4.2 Dyrehelse og forebygging Valg God og mat 45 Natur og enn resistens 59 for AMR 61 5.6 til natur og milj\u00f8 64 6 til Kapittel 3. 109 Vedlegg 3. Dyr, planter og mat til Kapittel 4. 110 Vedlegg 4. Natur og milj\u00f8 til oppdatering som er tilkommet etter som grunnlag for den hovedsak legge vekt p\u00e5 av fristen selektere for har vist milj\u00f8bakterier \u00c9n oppmerksomhet har fortsatt begrenset Norge i med h\u00f8yere forekomst i andre Nord -Europa det \u00e5r og det milliarder euro i direkte kostnader for helsetjenesten for standardisert overv\u00e5king av AMR sykdomsbyrde, - og mellominntektsland (17) , men ta lang tid tillegg til \u00e5 . f\u00f8rste halvdel tema (33;34) De fleste som ble spurt (84 klar over at spurte at antibiotika ikke er effektive mot virus, og bare litt over halvparten (56 %) vet at de ikke er mot og influensa barn h\u00f8sten 2017, 2018 og i 2019 i forbindelse med World Antibiotic Awareness Week (WAAW) (37) overf\u00f8ringsverdi Flere i Europa hatt stor suks ess med bruk av e vaksineskepsis en (24) . Vaksiner influenzae til men d mange til feriem\u00e5l der forekomsten h\u00f8yere enn i No rge. Mange med opprinnelse fra andre land som er bosatt varierer og problem og utg j\u00f8r 6 -7 av E. og blodkulturer. er utfordring i vedsak al med i 1 m\u00e5lt sammenlignet med 2012 . i n om at Norg e skal bli ett av de tre for av U antibiotikaresepter til under en tredjedel i 2020 sammenlignet med 2019 for norske 19 -\u00e5ringer . I andre land som USA, kan utviklingen ha en annen i ( DDD) til luftveisinfeksjoner, 18 % til urinveisinfeksjoner og 15 % til hud - og bl\u00f8tdelsinfeksjoner. Selv om l uftveis - og urinveisinfeksjoner representerer er antibiotika i prim\u00e6rhelsetjenesten i Norge siden 2014 (7). Dette er en trend som startet for ca . 10 \u00e5r siden, og er del av en internasjonal som har . Mens forskrivningen befolkningen, sykehjemsbeboere ca. 6-7 metenamin antibiotika -forskrivningen til mennesker, stort sett i form av (23 % versus % i 20 19 (7)), et kjent fenomen ogs\u00e5 fra andre rundt 7 % i 2009 til 4,6 % i 2018 (86) . Urinveisinfeksjoner er er g\u00e5tt I deltok bare 397 av 955 norske sykehjem i alle fire delunders\u00f8kelser, s\u00e5 her . i Norge g\u00e5r via fastleger, av tiltakene (RAK -l\u00e6ringsplattform. Per juni 2020 er RAK startet opp i etablering og Norge -19-pandemien er spesielt er (105) N\u00e6r 10 % av antibiotikaforbruket i Norge, helsetjenesten Overv\u00e5king av infeksjonsepidemiologi og resistens er ivaretatt i om til enkelte er beskrevet fra kan gi gode innenfor 6- 8 timer (122) intellige er h\u00f8yt arbeids 24 med strategien Antibiotikaresistens yr kan ogs\u00e5 v\u00e6re hos dyr sm\u00e5fe og gris. I 2019 ble terapianbefalinger anti - bakterielle midler til Group) kategoriseringen er for i forbindelse med \"antibiotics stewardship i og til -2019 det en reduksjon forbruket 21 sau, og b\u00e5de kg, til landdyr er blitt redusert med 21 % i t Figur 2). 2013 -2019 at oppdrettsfisk ble gang midler i kun 0,6 % - 1,6 % (5 -12 anlegg) av matfiskanleggene i sj\u00f8en (Vedlegg A, Figur fleste matproduserende dyr \u00f8kte fra 58 % til 77 % fra 2013 til 2019 og var hovedsakelig injeksjonspreparater (96 % - 99 %) som er 40 Antibiotikaresistens - Kunnskapshull, utfordringer A, ett av potensiale eller som er foresl\u00e5tt samles av EMA og for alle dyreartene nevnt i Tabell A 2. iden og gir en mer detaljert statusbeskrivelse sin AMR (145) I B, Tabell 2) dyr og omsettes i AMR forekomst E. coli de siste 10 \u00e5rene; fra ca. 5 % til ca. 1 6 % hos C. coli fra gris, og fra ca. 1 % til ca. 7 % hos C. jejuni fra kylling (7;149) . For innenlandssmittede mennesker de siste 10 \u00e5rene, fra under 10 % til ca. 20 %. Hos utenlandssmittede er fluorokinolonresistensen mye h\u00f8yere, >70 % (154) mellom fra land som har en h\u00f8yere forekomst av AMR i sin dyrepopulasjon, kan potensielt ha h\u00f8yere forekomst av er mer for fj\u00f8rfe (se detaljer MRSA hos gris. M\u00e5let for ESC -resistente coli var at forekomsten norske fj\u00f8rfebesetninger skulle kylling gikk drastisk ned, og i 2018 var det kun 0,4 % av flokkene og av kyllingkj\u00f8ttet som var positive for ESC- resistente coli bakterie regnet sentral og resistens hos mennesker , men d et er uklart om ESC-resistens hos pneumonia e hos dyr har tilsvarende Selv om det er lav - genotypene hos de med tanke p\u00e5 (162) andelen -resistente coli kan ha dyr og kj\u00f8tt som kilde da det stor av ESC endres av ESC - resistente E. coli hos mennesker som kan ha dyr som kilde, kan Europa. En eventuell etablering og videre spredning av C RE til i 2014 -rapporten og ogs\u00e5 av VKM i en rapport fra 2015 som vurderte hos Staphylococcus aureus , pseudintermedius Enterobacteriac eae. Et av sin handlingsplan er \u00e5 s tyrke har NORM -VET som belyser den norske enn i Norge , \u00f8kt hest er i Norge. Dette ble 2014 (148) i sin rapport med at sannsynligheten er neglisjerba r for at mennesker Norge, antas vesentlig for og resistens mot ampicillin i mer . om hand (172) . Rapporten konkluderer om er for nasjonale betydning AMR fra dyr, planter og mat mangelfull kunnskap o er ved fuktighet kunne f\u00f8re til mer ekstremv\u00e6r med p\u00e5f\u00f8lgende flom, som jen kan f\u00f8re til \u00f8kt spredning. Regional t \u00f8rke vil kunne medf\u00f8re for forekomst av AM R hos dyr og i mat , og b\u00f8r bidra Source av forekomsten under norske forhold for bakterier av klinisk betydning for betydning i utvikling og spredning \u00e5 samleinnog sammenstille -VET Arbeide videre med \u00e5 samle inn og sammenstille data forekomst av AMR i planter og plantebasert mat Dyr, planter og mat NORM -VET Samle og sammenstille data om forekomst av AMR knyttet asjonal handel med dyr, planter og mat Husdyr, planter for av resistente bakterier i representative fra kartlegging AMR r\u00f8drev viser at human populasjonstetthet har betydning for forekomst av AMR i norsk villfauna. Forekomst av AMR i E. coli fra i omr\u00e5der med lav av hos E. coli i tarmfloraen hos villrein og r\u00e5dyr i Norge. Det konkludere for fra r\u00f8drev fugler. Totalt ble 434 E. coli fra coli fra 3 % av pr\u00f8vene fra r\u00f8drev og i 9 % av pr\u00f8vene fra villfugl, samt kinolonresistente E. coli i 15 % av r\u00f8drevpr\u00f8vene, og i 6 % av villfuglpr\u00f8vene (160) generelle m\u00f8nsteret er de sam me som en i villsvinhelse - overv\u00e5kning ble det 2018 tverrsektoriell som patogener so m E. coli, pneumoniae Staphylococcus . for lav under \" \u00f8kosystem til mennesker og husdyr. Vi AMR i milj\u00f8et kan spres til spesielt som AMR. av AMR, ARG og andre - bindelser antibiotika at 106 bakterieceller (220) og over 108 virus partikler pr ml (221) . Det er antibiotikaresistens hos E. coli i skjellene lavt. I alt 38 % av isolatene viste resistens mot ett antibiotikum, mens fulgt under s\u00f8kelse av E. coli i 391 samlepr\u00f8ver av bl\u00e5skjell som en del av NORM/ NORM -VET i 2016 (160) . Her var 91 % isolatene f\u00f8lsomme % og 1,1 % var r esistent mot henholdsvis ett, to, tre og fire tillegg i slekten, av disse kan gi sykdom hos marine dyr og 12 av farvann har vi alle antibiotika det ble testet for, mens 35 % og 8 % hadde \u00f8kt resistens mot av mennesker . I et arbeid fra Venter konsentrasjonen klinisk relevans er dr\u00f8ftet i en VKM rap port fra . Denne inkluderte data fra 230 internasjonale fra veien. i Norge Siden 4 er i gang lokaliteter som tilf\u00f8rsel skip av de og til som kan gi utfordringer fo r dyr og mennesker. 5.2 Andre k resolusjon p\u00e5 basis av Kommisjonens melding \u00ab Strategic approach to pharmaceuticals in the environment \u00bb (235) , som kom i mars 2019. Arbeidet er del av European Green Deal (236) midler nasjonalt screeningprogram t ilf\u00f8rsel var lav, med niv\u00e5ene fastsatt under de publiserte environmental quality standards (EQS) og Predicted No -Effect Concentration kan AMR er i legemiddelstrategi november (237) orekomst andre forbindelser, er noe vi et kunnskapshull, da fisk organismer som mat avl\u00f8psvann \u00e5 ta i bruk den en globale AMR handlingsplanen til med ca. 5% i 2020, men mulighet er for oppsving i 2021 (256) de aller innovasjonsgrad (262) . Kun to nye pleuromutiliner ment for behandling av lungebetennelse. midlene ble godkjent av EMA i henholdsvis 2017 og 2019 ingen ceftolozan/ tazobactam og 2016 var ikke inkludert i WHOs rapport men er vurdert som nyskapende av Pew Charitable Trusts (263) cefalosporinet cefiderocol som av . \u00bb (CARB X), finansiert av USA og Wellcome Trust, har f\u00e5tt USD 502 the Pipeline for Anti -Infective Resistance\u00bb (REPAIR ) Impact Fund har USD 165 \u00e5 investere i t idligfase FoU (268) . Action Fund, skapt med bidrag fra over 20 er mot effektiviserings og -orienterte prosjekter (270) . 2018 viste en kartlegging av norske forskningsinnsatsen p\u00e5 AMR at en milliard den Globale AMR Fo U Hub, skapt i 2018 av G20 for nisme bli r (43) tre vaksine - og 2019 (277) , og Pfizers vaksine mot pneumokokker tjent e inn mer enn USD (278) . Pfizer m\u00e5tte imidlertid avslutte senfase inklusiv 14 mot M. tuber culos is pneumoniae (43) . Den \u00e5penbart mest etterspurte en premie p\u00e5 GBP 8 forekommer Norge i dag og sykdommer vi ikke har her til lands. God er for riktig behandling strategiske enn og aktuelle e nye antibiotika, men kun dem som har dokumentert verdi eller lav av resistens, og 2020 . EU skal starte mekanismer for to selskaper som har markedsf\u00f8ringstillatelse (MT) for humant benzylpenicillin, med MT -datoer fra 1951 og 1998, og to for fenoksymetylpenicillin, med MT -datoer fra 1970 og 1995 (287) . har innsyn hos disse produsentene, et situasjoner for i en unik situasjon og Source attribut den betydningen av forekomsten under norske forhold som seleksjonspress for AMR hos bakteri er klinisk betydning i og i en unik situasjon - stille av mat Planter NORM -VET Arbeide videre med \u00e5 samle inn og sammenstille data forekomst av AMR i planter og plantebasert mat Dyr, planter og mat NORM -VET Samle og data forekomst av AMR Andersson DI, Hughes D. Microbiological effects of sublethal levels of antibiotics. Nat Rev Microbiol 2014;12:465- 78. 2. Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, et al. Extensive impact of non- antibiotic drugs on human gut bacteria. Nature 2018;555:623- 8. 3. EU. A European Green Deal. Striving to be the first climate -neutral continent. Priorities 2019 -2024. -Palme J, Kotsakis S, Flach CF, et al. Identification of 76 novel B1 metallo --lactamases through large -scale screening of genomic and 2017;5:134. 5. McEwen Health Perspective. Microbiol Spectr 6. NORM/NORM- VET 2019. Usage of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Norway. Troms\u00f8 / Oslo. ISSN:1502 -2307 (print) JU, Sundsfjord A, Thune I, et al. Prevalence and population structure of Staphylococcus aureus nasal carriage in healthcare workers in a general population. The Troms\u00f8 Staph and Skin Study. Epidemiol al. MRSA prevalence among healthcare personnel in contact tracings in hospitals. Tidsskr Nor Legeforen 2018;138. T, Arvanitis Grigoras Extended -spectrum Beta -lactamase -Producing Enterobacte riaceae and Risk Factors Among Healthy Individuals: A Systematic Review and Metaanalysis. Clin Infect Dis J\u00f8rgensen SB, Liest\u00f8l K, Jenum PA. High rate of per oral mecillinam treatment failure in community -acquire d urinary tract infections caused by K, TM, PA. Fecal carriage of extended spectrum -lactamase producing Escherichia coli and Klebsiella pneumoniae after urinary tract infection - A three year prospective cohort study. PLoS One 2017;12:e0173510. 13. Rettedal spectrum -lactamase -producing Enterobacteriaceae among pregnant women in Norway: prevalence and maternal -neonatal transmission. J Perinatol 2015;35:907 -12. 14. de Kraker ME, Wolkewitz M, Davey PG, Koller W, Berger J, Nagler J, et al. Clinical impact of antimicrobial resistance in European hospitals: excess 84 Antibiotikaresistens Status 2020 Folkehelseinstituttet mortalit y and length of hospital stay related to methicillin- resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother 2011;55:1598- 605. 15. de Kraker ME, Wolkewitz M, Davey PG, Koller W, Berger J, Nagler J, et al. Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third -generation cephalosporins. J Antimicrob Chemother 2011;66:398- 407. 16. O'Neill CbJ. o n Antimicrobial Resistance. Tackling drug -resistant infections globally: final report and ME, Stewardson AJ, Harbarth S. Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050? PLoS the AMR cr isis. What are the avenues for policy action for countries in Europe? POLICY BRIEF 32. 2019. Available Hoxha A, Simonsen al. Attributable deaths and disability -adjusted life -years caused by infections with antibiotic -resistant bac teria in the EU and the European Economic Area in 2015: a population -level modelling analysis. Lancet Infect Dis 2019;19:56 20. Raoult D, Leone M, Roussel Y, Rolain JM. Attributable deaths caused by infections with antibiotic -resistant bacteria in Fra nce. Lancet Infect Dis 2019;19:128 -9. Furberg ASG. \u00d8, Enger H, Kacelnik O. The fight to keep resistance at bay, epidemiology of carbap enemase producing organisms (CPOs), vancomycin resistant enterococci (VRE) and methicillin resistant Staphylococcus aureus (MRSA) in Norway, 2006 - 2017. PLoS One 2019;14:e0211741. 23. Strategic Research and Innovation Agenda on Antimicrobial Resistance. Joint Programming Initiative on Antimicrobial Resistance, JPIAMR. JPIAMR Secretariat Swedish Research Council. 2019. Lacotte Y, MC. Infection prevention and control research priorities: what do we need to combat healthcare -associated infections an d antimicrobial resistance? Results of a narrative literature review and survey analysis. Antimicrob Resist Infect Control 2020;9:142. 85 Antibiotikaresistens aktuelle tiltak . 27. R. O'Neill report on antimicrobial resistance: funding for antimicrobial specialists should be na-enn-i-var/ 29. Hsu J. How covid -19 is accelerating the threat of antimicrobial resistance. BMJ 2020;369:m1983. 30. Calton B, Abedini N, Fratkin M. Telemedicine in the Time of Coronavirus. J Pain Symptom Manage 2020;60:e12- e4. 31. Bell BG, Schellevis F, Stobberingh E, Pringle M. A systematic review and meta -analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect Dis 2014;14:13. 32. Wernli D, J\u00f8rgensen PS, Harbarth S, Carroll arayan R, Levrat N, et al. Antimicrobial resistance: The complex challenge of measurement to inform policy and the public. PLoS Med 2017;14:e1002378. 33. Special Eurobarometer 445. Antimicrobial Resistance (in EU). Report. Fieldwork April 2016. Publicatio n June 2016. EU. Available from: https://data.europa.eu/euodp/en/data/dataset/S2107_85_1_445_ENG 34. Special Eurobarometer 478. Antimicrobial Resistance (in EU). Report. Fieldw ork September 2018. Publication November 2018. EU. Available from: https://data.europa.eu/euodp/en/data/dataset/S2190_90_1_478_ENG 35. Antimicrobial Resistance. Survey requeste d by the European Commission, Directorate -General for Health and Food Safety and co -ordinated by the Directorate -General for Communication. Special Stanojevic T, Halvorsen KH, et al. Knowledge o f antibiotics and antibiotic resistance among Norwegian pharmacy customers - a cross -sectional study. BMC Public Health 2019;19:66. 37. i -2020. VR, Trajano RP, Kravitz RL, Bell RA, Vora D, May LS. Communication interventions to promote the public's awareness of antibiotics: a systematic review. BMC Public Health 2019;19:899. 39. Allison R, Hay es C, Young V, McNulty CAM. Evaluation of an Educational Health Website on Infections and Antibiotics in England: Mixed Methods, User - Centered Approach. JMIR Form Res People' s Knowledge of Antibiotics and Vaccinations and Increasing This Knowledge Through Gaming: Mixed -Methods Study Using e -Bug. JMIR Serious VL, Berry M, Verlander NQ, Ridgway A, McNulty CA. Using debate to educate young people i n schools about antibiotic use and resistance: A before and after evaluation using a questionnaire survey. J Infect Prev 2019;20:281 -8. 86 Antibiotikaresistens . Status 2020 Folkehelseinstituttet 42. Wellcome Global Monitor. How does the world feel about science and health? 2019. Available from: https://wellcome.ac.uk/sites/default/files/wellcome - global- monitor -2018.pdf 43. Vaccines to tackle drug resistant infections. An evaluation of R&D opportunities. Boston Consulting Group (BCG) . 2018. Available from: https://vaccinesforamr.org/w p- content/uploads/2018/09/Vaccines_for_AMR.pdf N, Bergman H, Skidmore B, Klemm EJ, Villanueva G, et al. Impact of vaccination on antibiotic usage: a systematic review and meta-analysis. Clin Microbiol Infect 2019;25:1213 -25. 45. Direct and indirect effects of routine vaccination of children with 7 -valent pneumococcal conjugate vaccine on incidence of invasive Pant S, Brower C, R\u00f8ttingen JA, Klugman K, et al. Access to effective antimicrobials: a worldwide challenge. Lancet 2016;387:168- 75. 47. Sandvik Schilder AG, Sanders EA, et al. Pneumococcal conjugate vaccines for preventing acute otitis media in Coronaviruses -Associated Lower Respiratory Tract Infection Hospitalization in Children Living With and Without HIV (5/30/2020). The Lancet preprint Available at SSRN: https://ssrn.com/abstract=3618305 or http://dx.doi.org/10.2139/ssrn.3618305 . 2020. 50. Smith ER, Fry AM, Hicks LA, Fleming -Dutra KE, Flannery B, Ferdinands J, et al. Reducing Antibiotic Use in A mbulatory Care through Influenza Vaccination. Clin Infect Dis 2020. 51. Pressemedelelse - M\u00e5lgruppen for of adjuvanted trivalent influenza vaccine in older- age adults: a systematic review of economic evidence. Hum Vaccin Immunother 2019;15:1035- 47. 53. Barie PS, Narayan M, Sawyer Against Staphylococcus aureus Infections. Surg Infect (Larchmt) 2018;19:750 -6. 54. Lewnard JA, Lo NC, Arinaminpathy N, Frost I, Laxminarayan R. Childhood vaccines and antibiotic use in low - and middle -income countries. Nature 2020;581:94 -9. 55. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990 -2017: a systematic analysis for the Global Burden of Disease Study 2017. Lanc et 2018;392:1923- Hassali MA, Godman B, Fatima M, Ahmad Z, Sajid A, et al. Sale of WHO AWaRe groups antibiotics without a prescription in Pakistan: a simulated client study. J Pharm Policy Pract 2020;13:26. 57. Voor In 't Holt K, B, van der Schoor AS, Verbon Vos MC, et al. Acquisition of multidrug -resistant Enterobacterales during international travel: a systematic review of clinical and microbiological characteristics and meta -analyses of risk factors. Antimicrob Resist Control 2020;9:71. 58. Guzman- Herrador B, Vold L, Nygard K. Surveillance of travel- associated gastrointestinal infections in Norway, 2009 -2010: are they all actually imported? Euro Surveill 2012;17:20294. 59. Frost I, Van Boeckel TP, Pires J, Craig J, Laxminarayan R. Global geographic trends in antimicrobial resistance: the role of international travel. J Travel Med 2019;26. 60. Nasjonal alterations from 2005 -2020. WHO Collaborating Centre for Drug Statistics Methodology. Norwegian Institute of Public Health.[cited 30.11.20]. R, Molokhia M, Johnson AP, et al. Antibiotic management of urinary tract infection in elderly patients in primary care and its association with bloodstream infections and all caus e mortality: population based cohort study. BMJ 2019;364:l525. 63. Gulliford MC, Moore MV, Little P, Hay AD, Fox R, Prevost AT, et al. Safety of reduced antibiotic prescribing for self limiting respiratory tract infections in primary care: cohort study using electronic health records. BMJ 2016;354:i3410. 64. Gulliford MC , Sun X, Charlton J, Winter JR, Bunce C, Boiko O, et al. Serious bacterial infections and antibiotic prescribing in primary care: cohort study using electronic health records in the UK. BMJ Open 2020;10:e036975. 65. Cars T, Eriksson I, Granath A, Wettermark B, Hellman J, Norman C, et al. Antibiotic use and bacterial complications following upper respiratory tract infections: a population -based study. BMJ Open 2017;7(11):e016221. 66. M\u00f6lstad L\u00f6fmark S, Carlin K, Erntell M, Aspevall O, Blad L, et al. Les sons learnt during 20 years of the Swedish strategic programme against antibiotic resistance. Bull World Health Organ 2017;95:764 -73. 67. Sun X, Gulliford MC. Reducing antibiotic prescribing in primary care in England from 2014 to 2017: population -based c ohort study. BMJ Open 2019;9:e023989. 68. El Chakhtoura NG, Bonomo RA, Jump RLP. Influence of Aging and Environment on Presentation of Infection in Older Adults. Infect Dis Clin North Am 2017;31:593 -608. 69. Kline KA, Bowdish DM. in an po pulation. Curr Opin Microbiol 2016;29:63- 7. 70. Leibovici L, Paul M. Ethical dilemmas in antibiotic treatment: focus on the elderly. Clin Microbiol Darwin E, SarahTonkin C, Gorton C, Paul J, et al. The antibiotic course has had its day. BMJ 2017;358:j3418. 72. Spellberg B. The New Antibiotic Mantra- \"Shorter Is Better\". JAMA Intern Med 2016;176:1254- 5. Dinh A, Ghout I, Simo D, Zeller V, Issartel B, et al. Antibiotic treatment for 6 week s versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open- label, non -inferiority, randomised, Lancet 2015;385:875- 82. 74. Eliakim- Raz N, Yahav D, Paul M, Leibovici L. Duration of antibiotic treatment for acute pyelonep hritis and septic urinary tract infection -- 7 days or less versus longer treatment: systematic review and meta- analysis of randomized controlled OD, Duane TM, Evans HL, et al. Trial of short -course antimicrobial therapy for intraabdominal infection. N Engl J Med A, Quintana JM, Arriaga I, Intxausti M, et al. Duration of Antibiotic Treatment in Community -Acqui red Pneumonia: A Multicenter Randomized Clinical Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram- negative Bacteremia: A Noninferiority Randomized Controlled Trial. Edlund C, Giske CG, M\u00f6lstad S, Norman C, et al. Penicillin V four times daily for five days versus three times daily for 10 days in patients with pharyngotonsillitis caused by group A streptococci: randomised controlled, open Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co -infection and secondary infection in patients with COVID -19: a living rapid review and meta- analy sis. Clin Microbiol Infect 2020. 81. Oldenburg CE, T. Azithromycin for severe COVID- 19. The Lancet 2020;396:936- 7. 82. Bronzwaer SL, Cars O, Buchholz U, M\u00f6lstad S, Goettsch W, Veldhuijzen IK, et al. A European study on the relationship between antim icrobial use and antimicrobial SP, Thomsen RW. Decreasing trends, and geographical variation in outpatient antibiotic use: a population -based study in Central Denmark. BMC Infect Dis 2 019;19:337. 84. Tyrstrup M, Beckman A, M\u00f6lstad S, Engstr\u00f6m S, Lannering C, Melander E, et al. Reduction in antibiotic prescribing for respiratory tract infections in Swedish primary care - a retrospective study of electronic patient records. BMC Infect Dis 2016;16:709. 85. ECDC. European Centre for Disease Prevention and Control. Antimicrobial consumption in the EU/EEA, annual epidemiological report for 2018. ECDC; KB. gender gap in antibiotic prescribing: a cross -sectional analysis of English primary care. BMJ Open 2018;8:e020203. Nilsen S, R\u00f8rtveit G. New infrastructure for research in general practice. Tidsskr Nor Legeforen 2019;139. 92. Tonkin -Crine SK, Tan PS, van Hecke O, Wang K, Roberts NW, McCullough A, et al. Clinician -targeted interventions to influence antibiotic pr escribing behaviour for acute respiratory infections in primary care: an overview of systematic reviews. Cochrane Database Syst Rev 2017;9:Cd012252. 93. H\u00f8ye S, Gjelstad S, Lindb\u00e6k M. Effects on antibiotic dispensing rates of interventions to promote dela yed prescribing for respiratory tract infections in primary care. Br J Gen Pract 2013;63:e777 -86. 94. Gjelstad Dalen I, Lindb\u00e6k M. Improving antibiotic prescribing in acute respiratory tract infections: cluster randomised trial from Norwegian general practice (prescription peer academic detailing (Rx - PAD) study). BMJ 2013;347:f4403. 95. Mjelle AB, Hunskaar -of-hours prescription after screening with C reactive protein: a randomised co ntrolled study. BMJ Visits. 2019;143. de Bont E. Inapp ropriate Antibiotic Allergy Documentation in Health Records: A Qualitative Study on Family Physicians' and Pharmacists' Experiences. Ann Fam Med 2020;18:326 -33. 98. Little P, Stuart B, Smith S, Thompson MJ, Knox K, van den Bruel A, et al. Antibiotic presc ription strategies and adverse outcome for uncomplicated lower respiratory tract infections: prospective cough complication cohort (3C) study. BMJ 2017;357:j2148. 99. Rowe TA, Linder JA. Delayed Antibiotic Prescriptions in Ambulatory Care: Reconsidering a Problematic Practice. JAMA 2020. 100. Del Mar C, Glasziou P, Hayem M. Are antibiotics indicated as initial treatment for children with acute otitis media? A H\u00f8ye Phenoxymethylpenicillin Versus Amo xicillin for Infections in Ambulatory Care: A Systematic Review. Antibiotics (Basel) 2018;7. 102. Gulliford MC, Prevost AT, Charlton J, Juszczyk D, Soames J, McDermott L, et al. Effectiveness and safety of electronically delivered prescribing feedback and decision support on antibiotic use for respiratory illness in primary care: REDUCE cluster randomised trial. BMJ 2019;364:l236. Pulcini C, Henard S. Impact of selective reporting of antibiotic susceptibility test results on the appropriateness of antibiotics chosen by French general practitioners in urinary tract infections: a randomised controlled case -vignette study. International of EH, Nordeng H, R\u00f8 TB, Steinsbekk A. Requests for new oral antibiotic prescriptions in children within 2 days: a Norwegian population- based study. Fam Pract 2018;35:690- 7. Sihra A, Zakri R, Sahai A, Malde S. Nonantibiotic prevention and management of recurrent urinary tract infection. Nat Rev Urol 2018;15:750- 76. 107. Alberg Holen Forbes Ali A, Abouhajar A, Brennand C, Brown H, Carnell S, et al. ALternatives To prophylactic Antibiotics for the treatment of Recurrent urinary tract infection in women (ALTAR): study protocol for a multicentre, pragmatic, patient -randomised, non -inferiority trial. Trials A, Gudiol C, Pujol M, Alvarez -Pouso C, et al. Antibiotic prescription during the COVID- 19 pandemic: a biphasic pattern. Infection Control & Hospital Epidemiology 2020:1 JS, Hern\u00e1ndez -D\u00edaz S, Lipsitch M, et al. The distribution of antibiotic use and its association with antibiotic resistance. Elife 2018;7. 112. CDC. Core Elements of Hospital Antibiotic Stewardship Programs. Centers for Disease Control and Prevention.[cited]. stewardship: does it work in hospital practice? A review of the evidence base. Clin Nilsen RM, Charani E, et al. The effect of antibiotic stewardship interventions with stakeholder involvement in 91 Antibiotikaresistens multicentre, randomized controlled intervention study. Resist EJ, et al. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis 2016;62:e51 -77. 118. Dellit TH, Owe ns RC, McGowan JE, Jr., Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin I nfect Dis 2007;44:159- 77. 119. Wathne J. Bridging the evidence gap for implementing antibiotic stewardship in Norway: Interventions, process measures and patient outcomes related to antibiotic prescribing in hospitals [doktorgrad]. Bergen: Univeristetet T, M, Marchese A, Viscoli C, Rossolini GM. Rapid microbiological tests for bloodstream infections due to multidrug resistant Gram- negative bacteria: therapeutic implications. Clin Microbiol P, Fagot -Campagna A, Pulcini C, Thilly N. Impact of selective reporting of antibiotic susceptibility test results in urinary tract infections in the outpatient setting: a protocol for a pragmatic, prospective quasi -experimental trial. BMJ Open 2019;8:e025810. 122. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta -analysis. Lancet 2007;370:657 -66. Clin Microbiol Infect 2020;26:1324- 31. 124. Davey P, Marwick CA, Scott CL, Charani E, McNeil K, Brown E, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Chastre Fagon JY, Chevret S, Thomas F, Wermert D, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator -associated pneumonia in adults: a randomized trial. Pinto Arabi YM, Cook DJ, Hall R, et al. Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE) randomised clinical trial: study protocol. BMJ Open 2020;10:e038300. 127. Rice LB. The Maxw ell Finland Lecture: for the duration -rational antibiotic administration in an era of antimicrobial resistance and clostridium difficile. Clin Infect Dis 2008;46:491- 6. 128. EMA, 2016. EMA and EFSA Joint Scientific Opinion on measures to reduce the need t o use antimicrobial agents in animal husbandry in the European Union, and the resulting impacts on food safety (RONAFA) [cited]. ECDC, EFSA and EMA Joint Scienti c Opinion on a list of outcome indicators as regards surveillance of antimicrobial resistance and antimicrobial consumption in humans and food- producing av data. Union [cited]. 2020 Folkehelseinstituttet 139. ACCTING. Guidelines for collection, analysis and reporting of farm -level AMU, in the scope of EMA, 2019. Sales of veterinary antimicrobial agents in 31 European countries in 2017 2019. 141. EMA. Sales of veterinary antimicrobial agents in 31 European countries in 2017 Trends from 2010 to 2017 Ninth ESVAC report. -countries -2017_en.pdf 2019. Advice on implementing measures under Article 57(3) of Regulation (EU) 2019/6 on veterinary medicinal products - Report on specific requirements for the collection of data on antimicrobial medicinal products used in animals (EMA/CVMP/131097/2019). hos dyr og i status Norge i 2020. Veterin\u00e6rinstituttets rapportserie nr 147. law E. Publications Office of the EU. 2013/652/EU: Commission Implementing Decision of 12 November 2013 on the moni toring and reporting of antimicrobial resistance in zoonotic and commensal bacteria (notified under Assessment of antimicrobial resistance in the food chains in Norway. Scientific Opinion of the Panel o n microbiological hazards of the Norwegian Scientific Committee for Food Safety, ISBN: 978 -82-8259- 184-3, Agents and Occurrence of Antimicrobial. NORM/NORM -VET 2018. Resistance in Norway. Troms\u00f8 / K, Norstr\u00f6m M. Occurrence of quinolone resistant E. coli originating from different animal species in Norway. Vet Microbiol 2018;217:25 -31. Dissemination of Quinolone -Resistant Escherichia coli in the Norwegian Broiler and Pig Production Chains and Possible Persistence in the Broiler Production Environment. Appl Environ Microbiol Norstr\u00f6m M, et al. Comparative Genome Analyses of Wild Type - and Quinolone Resistant Escherichia coli Indicate Dissemination of QREC in the Norwegian Broiler Breeding Pyramid. Front Microbiol 2020;11:938. 153. EU. Commission implementing decision on the monitoring and reporting of antimicrobial resistance in zoonotic and commensal bacteria and repealing Commission - register/screen/documents/067935/3/consult 154. NORM/NORM -VET. Usage of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Norway. Troms\u00f8 / Oslo 2018. in Norway; Introduction to Pig and Eradication. Front Microbiol 2019;10:139. Methicillin -Resistant Staphylococcus aureus CC3 98 in Humans and Pigs in Norway: A \"One Health\" Perspective on Introduction and Transmission. Clin JS, Ramstad SN, To rp M, et al. Occurrence of and risk factors for extended -spectrum cephalosporin -resistant Enterobacteriaceae determined by sampling of all Norwegian broiler flocks during a six month period. PLoS One 2019;14:e0223074. 160. NORM/NORM Ahrenfeldt J, Mo SS, Sletteme\u00e5s JS, Steinbakk M, et al. Norwegian patients and retail chicken meat share cephalosporin -resistant Escherichia coli EM, Woolhouse MEJ, van Bunnik BAD. Are Food Animals Responsible for Transfer of Antimicrobial- Resistant Escherichia coli or Their Resistance Determinants to Human Populations? A Systematic Review. Foodborne Path og Dis 2018;15:467 -74. 163. de Been M, Lanza VF, de Toro M, Scharringa J, Dohmen W, Du Y, et al. Dissemination of cephalosporin resistance genes between Escherichia coli strains from farm animals and humans by specific plasmid lineages. PLoS Genet 2014;10:e1004776. 164. Dierikx C, van der Goot J, Fabri T, van Essen -Zandbergen A, Smith H, -spectrum --lactamase AmpC --lactamase -producing Chemother 2013;68(1):60- 7. 165. K\u00f6niger D, Gastmeier P, Kola A, Schwab F, Meyer E. Vegetarians are not less colonized with extended -spectrum --lactamase -producing bacteria than meat van Roon AM, van Hoek A, et al. Do vegetarians less frequently carry ESBL/pAmpC -producing Escherichia VKM. Assessment of the transfer of antimicrobial resistance between pets and humans in Norway. Oslo, Norway: Norwegian Scientific Committee for Food and Environment; https://vkm.no/english/riskassessments/allpublications/assessmentofthetransf GS, Grave K, Norstr\u00f6m M, et al. Imported food and feed as contributors to the introduction of plasmid-mediated colistin -resistant -7. 170. WHO. collaboration with OIE on Foodborne Antimicrobial Resistance: Role og 171. VKM. The link between antimicrobial resistance and the content of potentially toxic metals in soil and fertilising products. Opinion of the Panel on Biological Hazards of the Norwegian Scientific Committeefor Food Safety. Norwegian Scientific Committee for Food Safety (VKM), Oslo, Norway. VKM Assessment of the impact of wastewater and sewage sludge treatment methods on antimicrobial resist ance. Scientific opinion of the Panel on Microbial Ecology of the Norwegian Scientific Committee for Food and Environment. VKM (VKM), Oslo, N orway. The programme for hygiene in organic fertilizers in Norway 2017. Norwegian Food Safety Authorities. annual repot. 10 - Pesticides and antimicrobial resistance: from environmental compartments to animal and human infections. In: Grumezescu AM, editor. New Pesticides and Soil Sensors: L. From environment to clinic: the role of pesticides in antimicrobial resistance. Rev Panam Salud Publica 2020;44:e44. 176. Perlin DS, Rautemaa- Richardson A. The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect Clinical Use of Mold- Active Antifungal Azoles? Clin Infect Dis 2016;62:362- 8. 178. ECDC. Risk assessment on the impact of environmental usage of triazoles on the development and spread of resistance to medical triazoles in Aspergillus species. 2013. fumigatus: A global phenomenon originating in the environment? Med Mal Infect 2020;50:389- 95. 180. Norwegian Veterinary Institute. Azole resistance in a One Health perspective. Norsk handlingsplan https://www.regjeringen.no/no/dokumenter/meld. 20152016/id2468099/ M, Nesse LL, Sletteme\u00e5s JS, et al. What does the fox say? Monitoring antimicrobial resistance in the environment using wild red foxes as an indicator. PLOS ONE resistance in terrestrial wild mammal species in Norway - roe deer and w ild reindeer as indicators species. Rapport 6 - 2018. Norwegian Veterinary Institute. 186. VKM. resistance in wildlife - potential for dissemination. Opinion of the Panel on Microbial Ecology of the Norwegian Scientific Committee for Food and Antimicrobial resistance (AMR) from an environmental perspective - a short summary of assessments prepared by VKM in the period 2015 -2020. Scientific opinion of the Panel on Microbial Ecology of the Norwegian Scientific Committee for Food and Environment. Norwegian Scientific Committee for Food and Environment (VKM). Oslo, Norway. VKM -resistant Staphylococcus aureus in slaughtered reindeer in northern Finland and Norway. Acta Vet Scand 2017;59(1):2. 189. Carl V\u00e5ge Surveillance of wild boar health in Norway - result s from 2018 and 2019. Rapport 14 - 2020. Norwegian Veterinary Institute. Available M, et al. Scientists' warning to humanity: microorganisms and climate change. Nat Rev Microbiol 2019;17:569 -86. SF, Fisman D, Santillana M, Brownstein JS. Antibiotic Resistance Increases with Temperature. Cruz -Loya M, Savage V, Yeh P. Compounding Effects of Climate Warming and Antibiotic Resistance. iScience 2020;23:101024. 197. NIBIO 198. Nordg\u00e5rd Lmf. Prevalence of Antibio tic Resistance Marker Genes (ARMG) in Selected Environments in Norway - Reindeer. Project report, M -909|2017, Gen\u00d8k, Troms\u00f8, Norway. 2017. A BB, Pandey S. Variation of soil microbial population in different soil horizons. . J Microbiol Exp 2015;2:75- 8. 201. AMAP Assessment 2018: Biological Effects of Contaminants on Arctic Wildlife and Fish. Arctic Monitoring and Assessment Programme (AMAP), Troms\u00f8, Norway. vii+84pp. Available from: https://www.amap.no/documents/download/3080/inline 202. McCann CM, Christgen B, Roberts JA, Su JQ, Arnold KE, Gray ND, et al. Understanding drivers of antibiotic resistance genes in High Arctic soil ecosystems. Environ Int 2019;125:497- 504. 203. Sj\u00f6lund M, Bonnedah l J, Hernandez J, Bengtsson S, Cederbrant G, Pinhassi J, et al. Dissemination of multidrug -resistant bacteria into the Arctic. Emerg Infect Dis 2008;14:70- 2. 204. Antibiotic Resistance Can Spread Through The Air, Scientists Warn, And Yes You Should Be Ter rified. Science G, Wang X, Yang T, Su J, Qin Y, Wang S, et al. Air pollution could drive global dissemination of antibiotic resistance genes. ISME J 2020. 206. Schwermer CU, Krzeminski P, Wennberg AC, Vogelsang C, Uhl W. Removal of antibiotic resistant E. coli in two Norwegian wastewater treatment plants and by nano - and ultra -filtration processes. Water E. coli i to norske avl\u00f8psrenseanlegg 2018. VANN 2: 192 - The Travelling Particles: I nvestigating microplastics as possible transport vectors for multidrug resistant E. coli in the Weser estuary (Germany). Sci Total Environ 2020;720:137603. 212. Salta M, JA, Blache Briand JF. Environ Microbiol 2013;15:2879 -93. 213. Li J, Zhang K, Adsorption of antibiotics on microplastics. first look at sediment, biota and historical plankton samples from Lake Mj\u00f8sa and U, Rojas -Jimenez K, Grossart HP. Microplastic increases gene exchange in ecosystems. Pollut 2018;237:253- 61. 216. Dafale NA, Srivastava S, Purohit HJ. Z oonosis: An Emerging Link to Antibiotic Resistance Under \"One Health Approach\". Indian J Selection of substances for the 3rd Watch List under the Water Framework Directive, EUR 30297 EN, Luxembourg: Publications Office of the European Union, 2020, ISBN 978 -92-76-19426 -2, doi:10.2760/194067, JRC121346. 2020. Available from: https://images.chemycal.com/Media/Files/third_watch_list_report_pdf.pdf 219. European Commission. A European One Health Action Plan against Antimicrobial Resistance (AMR). 2017. Available from: https://ec.europa.eu/health/sites/health/files/ Courties C, Muyzer G , Lebaron P. Genetic diversity of total, active and culturable marine bacteria in coastal seawater Aquatic microbial ecology 2000;23. 221. Bratbak G H M, Thingstad TF og Tuomi P. Dynamics of virus abundance in costal seawater FEMS Microbiology ecology 1996;19. 222. Grevskott D. Bivalve mollusks as tools for monitoring antibiotic resistance in the marine environment, PhD thesis, University of Bergen. 20 20. 223. Svanevik CS. GD, Bernssen LS, Lunestad BT i skjel. 2018. Escobar LE, Ryan SJ, Stewart -Ibarra AM, Finkelstein JL, King CA, Qiao H, et al. A global map of suitability for coastal Vibrio cholerae under current and future climate conditions. Acta Trop 2015;149:202- 11. 225. Naseer U BH, Angeloff L, Nyg\u00e5rd K, Vold L and Macdonald E,. Cluster of septicaemia and necrotizing fasciitis following exposure to high seawater temperatures in southeast Norway, June to August 2018. International Journal of Infectious Diseases 2019;79. 226. H\u00e5konsholm F LB, Aguirre S\u00e1nchez JR, Martinez - Urtaza J, Marathe NP, and Svanevik CS,. Vibrios from the Norwegian marine environment: Characterization of associated antibiotic resistance and virulence genes. MicrobiologyOpen 2020;(2020;9:e1093):1 -19. 227. Tryland M, Nesbakken -Ogden D, Lunestad BT. Human pathogens in marine mammal meat - a northern perspective. Zoonoses Public Health 2014;61:377- 94. 228. Venter H. Antimicrobial resistance in the marine environment: MIC profiles of bacteria isolated from whale and seal faeces. Project report, M -1260|2019, Gen\u00d8k, Troms\u00f8, Norway. 229. Radisic V, Nimje PS, Bienfait AM, Marathe NP. Marine Plastics from Norwegian West Coast Carry Potentially Virulent Fish Pathogens and Opportunistic Human 101 Antibiotikaresistens - Variants Antibiotic Resistance Genes. Microorganisms 2020;8. 230. Debroas D, Siguret C. Viruses as key reservoirs of antibiotic resistance genes in the environment. ISME J 2019;13(11):2856- 67. 231. Initiatives for Addressing Ant imicrobial Resistance in the Environment: Current Situation and Challenges. 2018.[cited]. Available from: https://wellcome.ac.uk/sites/default/files/ antimicrobial- resistance - environment -report.pdf 232. Singer AC, Shaw, H., Rhodes, V. and Hart, A. Review of Antimicrobial Resistance in the Environment and Its Relevance to Environmental Regulators. . Front Microbiol 2016;7. 233. Singer AC, Shaw H, Rhodes V, Hart A. Review of Antimicrobial Resistance in the Environment and Its Relevance to Environmental Regulators. Front Microbiol 2016;7:1728. 234. Wang Y, Lu J, Engelst\u00e4dter J, Zhang S, Ding P, Mao L, et al. Non -antibiotic pharmaceuticals enhance the tran smission of exogenous antibiotic resistance genes through bacterial transformation. ISME J 2020;14:2179 -96. 235. European commision. Pharmaceuticals in the environment. Report on Strategic Approach to Pharmaceuticals in the Environment. Pharmaceuticals in the environment: 2020. Gree n Deal. Striving to be the first climate - neutral continent. Action plan. Strategic priorities 2019 -2024. 2020. Available from: https://ec.europa.eu/info/strategy /priorities -2019- 2024/european - green -deal_en 237. European Commission. Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions: Pharmaceutical Strategy for Europ e (SWD (2020) 286 final). 25. november 2020. Available from: https://ec.europa.eu/health/sites/health/files/human - use/docs/pharmastrategy_com202 0-761_en.pdf 238. Kampf G. Biocidal Agents Used for Disinfection Can Enhance Antibiotic Resistance in Gram -Negative Species. Antibiotics (Basel) 2018;7(4). 239. Pidot SJ, Gao W, Buultjens AH, Monk IR, Guerillot R, Carter GP, et al. Increasing tolerance of hospital Enteroco ccus faecium to handwash alcohols. Sci Transl Med 2018:10. 240. NIVA. Screening programme 2015. Pharmaceuticals & hormones. Environmental monitoring. M- 597/2016. Available from: https://www.miljodirektoratet.no/globalassets/publikasjoner/m597/m597.pdf 241. Larsson DG, de Pedro C, Paxeus N. Effluent from drug manufactures contains extremely high levels of pharmaceuticals. J Hazard Mater 2007;148:751 -5. 242. Jensen J, Kyvsgaard NC, Battisti A, Baptiste KE. Environmental and public health related risk of veterinary zinc in pig production - Using Denmark as an example. Environment International 2018;114:181 -90. 243. Mattilsynet. Statens A, Gaschet M, Louren\u00e7o J, Kennedy SP, Wiest L, et al. Hospital discharges in urban sanitation systems: Long -term monitoring of wastewater resistome and microbiota in relationship to their eco -exposome. Water Res X 2020;7:100045. 245. Orn et al. Screening of faecal bacteria and antibiotic resistance in urban wastewater and recipient river surface water, Sveriges Landbruksuniversitet og Svenske milj\u00f8myndigheter[cited ]. Available Ray J, Bj\u00f8rsvik M, Venter H, T\u00f8mmer\u00e5s B, Olsen E, et al. Antimicrobial Resistance in Selected Environments in Norway: Occurrence of Antimicrobial resistant bacteria (ARB) and antimicrobial resistant genes (ARG) associated with wastewater C. Whole genome sequencing and antibiotic diffusion assays, provide new insight on drug resistance in the genus Pedobacter. FEMS Microbiol Ecol 2020;96. 248. Ullmann IF, Tunsj\u00f8 HS, Andreassen M, Nielsen KM, Lund V, Charnock C. Detection of Ami noglycoside Resistant Bacteria in Sludge Samples From Norwegian Drinking Water Treatment Plants. Front Microbiol 2019;10:487. 249. Global antimicrobial resistance surveillance system (GLASS) report: early implementation 2020. ISBN 978 -92-4-000558 -7 (elect ronic version). 2020. 250. WHO. Global antimicrobial resistance and use surveillance system (GLASS) report. Early implementation 2020. World Health Organization. Available from: https://www.who.int/glass/resources/publications/early -implementation - report -2020/en/ 251. Carraro L, W\u00fcthrich R, Altermatt F. Environmental DNA allows upscaling spatial patterns of biodiversity in freshwater ecosystems . Nat Commun 2020;11:3585. 252. Yuan K, Wang X, Chen X, Zhao Z, Fang L, Chen B, et al. Occurrence of antibiotic resistance genes in extracellular and intracellular DNA from sediments collected from two types of aquaculture farms. Chemosphere 2019;234:520 -7. 253. Jiang H, Zhou R, Zhang M, Cheng Z, Li J, Zhang G, et al. Exploring the differences of antibiotic resistance genes profiles between river surface water and sediments using metagenomic approach. Ecotoxicol Environ Saf 2018;161:64 -9. 254. Fang H, Han L, Zhang H, Long Z, Cai L, Yu Y. Dissemination of antibiotic resistance genes and human pathogenic bacteria from a pig feedlot to the surrounding stream and agricultural soils. J Hazard Mater 2018;357:53 -62. 255. Group WB, editor. Jonas OB, Irwin A, Berthe FCJ, Le Gall FG, Marquez PV. Drug - resistant infections : a threat to our economic future (Vol. 2) : final report. Washington DC: World Bank Group; 2017. Available from: tiltak . Status 2020 Folkehelseinstituttet 256. The World Bank. Pandemic, Recession: The Global Economy in Crisis. Washington DC: 2020. Available https://www.worldbank.org/en/publication/global -economic -prospects 257. -action Ministers. Okayama Declaration of G20 Health Ministers. 2019. Available f rom: http://www.g20.utoronto.ca/2019/2019- g20-health.html 259. \u00c5rdal C, Findlay D, Savic M, Carmeli Y, Gyssens I, Laxminarayan R, et al. Revitalizing the antibiotic pipeline: Stimulating innovation while driving sustainable use and global access. 2018. 260. Daniel G, McClellan M, Schneider M, Qian J, Lavezzari G, de Graffenreid E. Value -based strategies for encouraging new development of antimicrobial drugs: Duke -Margolis center for health policy. 2017. 261. Resistance ICGoA. No Time to Wait -Securing the Future from Drug -resistant Infections. 2019. Report to the Secretary General of the Nations. Available from: https://www.who.int/antimicrobial -resistance/interagency -coordination - group/final -report/en/ 262. World Health Organization. 2019 antibacterial agents in clinical development: an analysis of the antibacterial clinical develop ment pipeline[cited]. 263. Pew Charitable Trusts. Antibiotics Currently in Global Clinical Development[cited]. Available from: https://www.pewtrusts.org/en/research- and-analysis/data -visualizations/2014/antibiotics -currently -in-clinical- development 264. Taylor NP. Melinta files for bankruptcy in another dark day for antibiotics. Fierce Biotech 2/1 2020. Available from: https://www.fiercebiotech.com/biotech/melinta -files-for-bankruptcy -another - dark -day-for-antibiotics 265. World Health Organization. Global priority list of antibiotic -resistant bacteria to guide research, discovery, and the development of new antibiotics. Geneva: World Health Organization; 2017. e from: https://www.repair R&D HUB[cited 31.11.20]. Available from: https://globalamrhub.org/ 273. National Institute for Health and Care Excellence. Models for the evaluation and purchase of antimicrobialsLondon: NICE \u00c5rdal C, Baraldi E, Ryan K, Plahte J. An assessment of the future impact of alternative technologies on antibiotics markets. Journal of pharmaceutical policy and practice 2016;9:34. 277. Banerje e A, Aripaka P. GSK sees shingles vaccine sales rising, as free cash flow concerns weigh. Reuters 5/1 2019. Available products[cited]. Available from: https://en.wikipedia.org/wiki/List_of_largest_selling_pharmaceutical_products 279. Oslo universitetssykehus. A range of different COVID- 19 vaccines are already being tested in huma ns. But how will the vaccines actually T. COVID -19 vaccines: early success and remaining challenges. Lancet 2020;396:868- 9. 281. Value Dx. What is Value Dx?[cited]. Available from: https://valu e- dx.eu/index.php/what- is-value Povoa P. Biomarker -guided antibiotic therapy \u2014strengths and limitations. Annals of translational medicine 2017;5. 283. Longitude Prize. [cited]. Available from: https://longitudeprize.org/ 284. Unitaid. Unitaid's investment in tuberculosis hits record levels with new grant for diagnostic technologies[cited]. Health Organization. Meeting report: antibiotic shortages: magnitude, causes an d possible on quantification of veterinary antimicrobial usage at herd level and analysis, communication and benchmark ing to improve responsible usage AI Kunstig intellegens AMEG Antimicrobial Advice Combating antibiotic resistans bacteria biopharmaceutical accelerator CDC Centre for Disease Prevention and Control CVMP Committe for Medicinal Products for Alimentarius utvikler d\u00f8gndoser EARS -net European Antimicrobial Resistance Surveillance Network ECDC European Centre for Disease Prevention and Control EEA European Economic Area (Det europeiske \u00f8konomiske samarbeidsomr\u00e5det) Safety Authority betalaktamase EU European Union (Den europeiske union) FAO UN Food and Agriculture Organisation 107 Antibiotikaresistens - Kunnskapshull, Antibiotic partnership GAVI Global Vaccine Alliance (Den globale vaksinealliansen) - og omsorgsdepartementet IDSA Infectious Disease Society of America IMI Innovative Medicine Initiative JPIAMR The Joint Programming Initiative on Antimicrobial Resistance KAS Nasjonal for LMIC - and middle income countries (Lav - og middelinntekstland) LIS Leger i spesialisering MALDI -TOF studie REPAIR The Replenishing and Enabling the Pipeline for Anti -Infective Resistance (REPAIR) Impact Fund SARS -CoV -2 Severe acute WAAW World awareness week WHO og helsetjeneste til Kapittel 3. Vaccines to tackle drug resistant infections. An evaluation of R&D opportunities. Boston Consulting Group (BCG). 2018. The report was commissioned by the Wellcome Trust and completed by The Boston Consulting Group (BCG). Through the process of making det ailed recommendations specific to each pathogen, this report also identified knowledge gaps shared across multiple pathogens and increased uptake. Based upon these, several cross -cutting activities have been proposed which, if addressed in a coordinated ma nner, would stimulate development of vaccines for all pathogens with high levels of AMR Vaccine Stage of vaccine Comments H. influenzae vaccine Increase uptake ~ 70% uptake S. pneumoniae vaccine ~ 40% uptake S. Typhi vaccine New conjugated, pre -qualified by the WHO and is supported by Gavi for introduction in 2019, focus on successfully introducing a vaccination program E. coli (enteric) vaccine Bring to market Difficult, Inclusion of LT toxoid and fimbrial antigens in a potential vaccine may help cover 70 -80% of strains non-typhoidal Salmonella vaccine technically promising and potentially impactful, given high disease burden in Africa vaccine against Shigella major opportunity in this segment due to high incidence and significant associated mortality vaccine development for M. tuberculosis Advance early R&D Pathogens on the WHO list. Health impact and AMR threat (due to sub -optimal effectiveness of BCG vaccine). Improve translatability N. gonorrhoeae Pathogens on the WHO list. Improve Translatability. P. aeruginosa Pathogens on the WHO list. Pre -clinical research S. aureus Pathogens on the WHO list. Pre -clinical research E. coli (urinary) Pathogens on the WHO list. Pre -clinical research Pathogens on the WHO list that are not currently well -suited to vaccine Collect data, explore alternatives . Referanse: Vaccines to tackle drug resistant infections. An evaluation of R&D opportunities. Boston Consulting Group (BCG). 2018. https://vaccinesforamr.org/wp - til Kapittel 4 Produksjon av kj\u00f8tt og oppdrettsfisk i Norge i 2019 er vist i Figur A 1. Figur A 1 . Andel slaktet (tonn) per hester p\u00e5 g\u00e5rdsbruk her i landet i om forbruksm\u00f8nster A 2 behandlinger og ble behandlet med en kur antibakterielle midler i \u00e5rene av antibakterielle til landdyr og grossister av veterin\u00e6re antibakterielle midler av 3. andre er vist i Tekstboks A 2 I 2019 ble ny A 2 . Animal species for which antimicrobial use data are suggested to be submitted to the European Medicines Agency and the timelines (modified Table 3 , EMA/CVMP, 2019) For 2023 For 2026 For 2029 Cattle Aggregated for all categories, including bovine under 1 year of age, specifying AMU for bovine < 1 year(a) Cattle Aggregated for all categories, including bovine under 1 year of age, specifying AMU for bovine < 1 year(a) Cattle Aggregated for all categories, including bovine under 1 year of age, specifying AMU for bovine < 1 year(a) Pigs Pigs Pigs Poultry Gallus gallus For each species aggregated for all production categories/stages: breeders, chicken, layers For each species aggregated for all production categories/stages: breeders, chicken, layers For each species aggregated for all production categories/stages: breeders, chicken, layers Sheep Sheep Goats Goats Finfish Finfish Horses - both food -producing and non food -producing Horses - both food -producing and non food -producing Rabbits (food -producing) Rabbits (food -producing) Any other food -producing animals Any other food -producing animals Dogs Cats Fur animals Mink Fox (a) For Member States where production is more than 10 000 tonnes slaughtered/year in line with Commission Implementing Decision 2013/652/EU. Referanser : EMA, 2019. Sales of veterinary antimicrobial agents in 31 European countries implementing measures under Article 57(3) of Regulation (EU) 2019/6 on veterinary medicinal products - Report on specific requirements for the collection of data on antimicrobial medicinal products used in behandling -2017 ( Figur 3 i Veterin\u00e6rinstituttets rapport Resistensforekomst k nowledge gaps on azole resistance in a One Health perspective. Report 3 -2019: Azole resistance in a One resistance in Aspergillus fumigatus: recent insights and challenges for patient management. https://www.clinicalmicrobiologyandinfection.com/article/S1198 -743X(18)30780 - 8/fulltext Forskrift 2016 Prevalence of Antibiotic Resistance Marker Genes (ARMG) in Selected Environments Gen\u00d8k - Senter for biosikkerhet Antimicrobial resistance in selected environments in Norway. Occurrence of antimicrobial resistant bacteria (ARB) and antimicrobial resistant genes (ARG) associated with wastewater treatments plants Gen\u00d8k - Senter for biosikkerhet Antimicrobial resistance in the Norwegian environment - red fox as an indicator Veterin\u00e6rinstituttet \u00c5r 2017 Kartlegging 3 resistance the biocides Milj\u00f8direktoratet "}